Association of early-onset diabetes, prediabetes and early glycaemic recovery with the risk of all-cause and cardiovascular mortality
Kim SM, Lee G, Choi S, et al.
Diabetologia. 2020;63(11):2305-2314
Leggi
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta‐analysis of randomized controlled trials
Zhou Y, Chi J, Huang Y, et al.
Diabet Med. Pub. online 30 September 2020
Leggi
Metabolic phenotypes of early gestational diabetes mellitus and their association with adverse pregnancy outcomes
Immanuel J, Simmons D, Harreiter J, et al.
Diabet Med. Pub. online 29 September 2020
Leggi
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials
Mann JFE, Hansen T, Idorn T, et al
Lancet Diabetes Endocrinol. 2020;S2213-8587(20)30313-2
Leggi
Once-weekly insulin for type 2 diabetes without previous insulin treatment
Rosenstock J, Bajaj HS, Janež A, et al.
N Engl J Med. Pub.online 22 September 2020
Leggi
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon CP, Pratley R, Dagogo-Jack S, et al.
N Engl J Med. Pub. online 23 September 2020
Leggi
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Filion KB, Lix LM, Yu OHY, et al.
BMJ. 2020;370:m3342
Leggi
Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for covid-19: the Pisa COVID-19 Study
Coppelli A, Giannarelli R, Aragona M, et al.
Diabetes Care. 2020;43(10):2345-48
Leggi
Dapagliflozin in patients with chronic kidney disease
Heerspink HJL, Stefànsson BV, Correa-Rotter R, et al.
N Engl J Med. Pub. online 24 September 2020
Leggi